Cargando…

Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells

BACKGROUND: Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastrol’s anti-tumor effects through HSP70 interference has been reported, but becaus...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Bin, Zhang, Xue, Cao, Fanfan, Wang, Ying, Xu, Limin, Cao, Lu, Yang, Chunxin, Li, Maoquan, Uzan, Georges, Zhang, Denghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975845/
https://www.ncbi.nlm.nih.gov/pubmed/24589236
http://dx.doi.org/10.1186/1471-2407-14-146
_version_ 1782310195772260352
author Peng, Bin
Zhang, Xue
Cao, Fanfan
Wang, Ying
Xu, Limin
Cao, Lu
Yang, Chunxin
Li, Maoquan
Uzan, Georges
Zhang, Denghai
author_facet Peng, Bin
Zhang, Xue
Cao, Fanfan
Wang, Ying
Xu, Limin
Cao, Lu
Yang, Chunxin
Li, Maoquan
Uzan, Georges
Zhang, Denghai
author_sort Peng, Bin
collection PubMed
description BACKGROUND: Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastrol’s anti-tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring. METHODS: In this work, we explore three alternative strategies to control HSP70 elevation: (1) Searching for cancer cell types that show no HSP70 elevation in the presence of celastrol (thus recommending themselves as suitable targets); (2) Modifying HSP70-inducing chemical groups, i.e.: the carboxyl group in celastrol; and (3) Using signaling molecule inhibitors to specifically block HSP70 elevation while protecting and/or enhancing anti-tumor effects. RESULTS: The first strategy was unsuccessful since celastrol treatment increased HSP70 in all 7 of the cancer cell types tested, this result related to HSF1 activation. The ubiquity of HSF1 expression in different cancer cells might explain why celastrol has no cell-type limitation for HSP70 induction. The second strategy revealed that modification of celastrol’s carboxyl group abolished its ability to elevate HSP70, but also abolished celastrol’s tumor inhibition effects. In the third strategy, 11 inhibitors for 10 signaling proteins reportedly related to celastrol action were tested, and five of these could reduce celastrol-caused HSP70 elevation. Among these, the peptide deformylase (PDF) inhibitor, actinonin, could synergize celastrol’s proliferation inhibition. CONCLUSIONS: Concurrent use of the chemical agent actinonin could reduce celastrol’s HSP70 elevation and also enhance proliferation inhibition by celastrol. This combination presents a novel alternative to siRNA technology and is worth further investigation for its potentially effective anti-tumor action.
format Online
Article
Text
id pubmed-3975845
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39758452014-04-17 Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells Peng, Bin Zhang, Xue Cao, Fanfan Wang, Ying Xu, Limin Cao, Lu Yang, Chunxin Li, Maoquan Uzan, Georges Zhang, Denghai BMC Cancer Research Article BACKGROUND: Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastrol’s anti-tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring. METHODS: In this work, we explore three alternative strategies to control HSP70 elevation: (1) Searching for cancer cell types that show no HSP70 elevation in the presence of celastrol (thus recommending themselves as suitable targets); (2) Modifying HSP70-inducing chemical groups, i.e.: the carboxyl group in celastrol; and (3) Using signaling molecule inhibitors to specifically block HSP70 elevation while protecting and/or enhancing anti-tumor effects. RESULTS: The first strategy was unsuccessful since celastrol treatment increased HSP70 in all 7 of the cancer cell types tested, this result related to HSF1 activation. The ubiquity of HSF1 expression in different cancer cells might explain why celastrol has no cell-type limitation for HSP70 induction. The second strategy revealed that modification of celastrol’s carboxyl group abolished its ability to elevate HSP70, but also abolished celastrol’s tumor inhibition effects. In the third strategy, 11 inhibitors for 10 signaling proteins reportedly related to celastrol action were tested, and five of these could reduce celastrol-caused HSP70 elevation. Among these, the peptide deformylase (PDF) inhibitor, actinonin, could synergize celastrol’s proliferation inhibition. CONCLUSIONS: Concurrent use of the chemical agent actinonin could reduce celastrol’s HSP70 elevation and also enhance proliferation inhibition by celastrol. This combination presents a novel alternative to siRNA technology and is worth further investigation for its potentially effective anti-tumor action. BioMed Central 2014-03-04 /pmc/articles/PMC3975845/ /pubmed/24589236 http://dx.doi.org/10.1186/1471-2407-14-146 Text en Copyright © 2014 Peng et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Peng, Bin
Zhang, Xue
Cao, Fanfan
Wang, Ying
Xu, Limin
Cao, Lu
Yang, Chunxin
Li, Maoquan
Uzan, Georges
Zhang, Denghai
Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
title Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
title_full Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
title_fullStr Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
title_full_unstemmed Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
title_short Peptide deformylase inhibitor actinonin reduces celastrol’s HSP70 induction while synergizing proliferation inhibition in tumor cells
title_sort peptide deformylase inhibitor actinonin reduces celastrol’s hsp70 induction while synergizing proliferation inhibition in tumor cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975845/
https://www.ncbi.nlm.nih.gov/pubmed/24589236
http://dx.doi.org/10.1186/1471-2407-14-146
work_keys_str_mv AT pengbin peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT zhangxue peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT caofanfan peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT wangying peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT xulimin peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT caolu peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT yangchunxin peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT limaoquan peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT uzangeorges peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells
AT zhangdenghai peptidedeformylaseinhibitoractinoninreducescelastrolshsp70inductionwhilesynergizingproliferationinhibitionintumorcells